About Imunon Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://imunon.com/
Frequently Asked Questions
What is the 52-week range for IMNN?
The 52-week high is $5.55 and the 52-week low is $1.26.
What is the P/E ratio for IMNN?
The P/E ratio data is currently unavailable.
What is the dividend yield for IMNN?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -314.90%.
What is the Net Profit Margin?
The Net Profit Margin (TTM) is -6901.92%.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.66.
Analyst Recommendation Trends
Wall Street analyst consensus for IMNN over the last few months:
Latest IMNN News
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Elutia (NASDAQ:ELUT) stock moved upwards by 17.2% to $0.94 during Thursday's after-market session. The market value of their outstanding shares is at $34.9 million. Intelligent Bio Solutions (NASDAQ:INBS)
IMNN: R&D Day Highlights IMNN-001 Data in Frontline Ovarian Cancer
By David Bautz, PhD NASDAQ: IMNN READ THE FULL IMNN RESEARCH REPORT Business Update R&D Day Highlights IMNN-001 in Advanced Ovarian Cancer On September 23, 2026, Imunon, Inc. (NASDAQ: IMNN) held an R&D Day to discuss the IMNN-001 program, which included a discussion on the use of localized IL-12 in cancer therapy, translational data that showed IMNN-001 is preferentially taken up by
IMUNON Converts $1.2 Million of Debt-to-Equity
Unique investment vehicle provides efficient access to equity capitalOutstanding debt of the original Note lowered by approximately 43% No issuance of common stock or dilutive warrants LAWRENCEVILLE, N.J., Sept. 29, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), (“IMUNON” or the “Company”), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that it has entered into an Exchange Agreement, under which $1.2 million of outstanding debt, together wi
Imunon, Inc. (IMNN) Shareholder/Analyst Call - Slideshow
2026-09-24. The following slide deck was published by Imunon, Inc.
IMUNON Makes the Frontline Case for Phase 3 IMNN-001 Study: 14.7-Month OS Signal, Historical IL-12 Safety Barriers Overcome, Enrolling Ahead of Plan
2026 R&D Day presentation highlights include: Review of final Randomized Phase 2 overall survival results Supportive Preliminary MRD Study Data and translational findings Pathway to confirmatory readout in OVATION 3 Testimonial conversation with an OVATION 1 participant now 10 years from diagnosis LAWRENCEVILLE, N.J., Sept. 24, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today is presenting an update on its
IMUNON Reports Overall Survival Results, Advances Phase 3 OVATION 3 Trial
2026 R&D Day presentation highlights include:Review of final Randomized Phase 2 overall survival resultsSupportive Preliminary MRD Study Data and translational findingsPathway to confirmatory readout in OVATION
Imunon, Inc. (IMNN) Shareholder/Analyst Call Transcript
Imunon, Inc. (IMNN) Shareholder/Analyst Call September 23, 2026 10:00 AM EDTCompany ParticipantsStacy Lindborg - President, CEO & DirectorDouglas V.
IMUNON Reports Independent Data Monitoring Committee Recommends Continued Phase 2 Development of IMNN-001 Following Favorable Safety Review
Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to date No cytokine release syndrome, systemic toxicities or serious immune-related adverse events observed to date, reinforcing IMNN-001's differentiated safety profile as an IL-12-based immunotherapy MRD study has now demonstrated the safety and tolerability of IMNN-001 both in combination with bevacizumab and in the maintenance setting Recommenda
IMUNON Says Independent Monitoring Committee Recommends Continuing IMNN-001 Phase 2 Study Without Modification
Independent Data Monitoring Committee recommends the ongoing Phase 2 MRD study continue without modification following its review of all safety data to dateNo cytokine release syndrome, systemic toxicities or serious
IMUNON Enters Cooperative Research and Development Agreement with National Cancer Institute to Advance Clinical Development of IMNN-001
Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new indications and combination regimens IMUNON retains ownership of its background intellectual property with an opportunity to expand its IP through this collaboration LAWRENCEVILLE, N.J., Sept. 10, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced it has entered into a Cooperative Research and Development
IMUNON Enters Into CRADA With National Cancer Institute To Advance DNA-Based IL‑12 Immunotherapy IMNN‑001
Collaboration with NCI's Cancer Therapy Evaluation Program (CTEP) will evaluate IMNN-001in new indications and combination regimensIMUNON retains ownership of its background intellectual property with an opportunity
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 48.8% to $3.63 during Thursday's pre-market session. The market value of their outstanding shares is at $1.6 million. AEON Biopharma (AMEX:AEON) stock
IMUNON Announces Full Agenda and Speaker Lineup Ahead of 2026 R&D Day Highlighting IMNN-001 Clinical Progress
Investors, media and stakeholders are invited to join in person in New York City or via live webcast on Wednesday, September 23, 2026, at 10:00 a.m. ET LAWRENCEVILLE, N.J., Sept. 09, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced the agenda and speaker lineup for its upcoming R&D Day highlighting IMNN-001, the Company’s investigational IL-12 immunotherapy. The event will be held at the Sofitel
IMUNON To Discuss OVATION 1 Clinical Study At Its Sept. 23 R&D Day
IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced the agenda and speaker lineup for its upcoming R&D Day highlighting IMNN-001, the
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-25 | Faller Douglas Vincent | +4,390 | $1.41 | $6,190 |
| 2026-09-25 | Lindborg Stacy | +6,697 | $1.41 | $9,443 |
| 2026-09-25 | Tardugno Michael H | +7,169 | $1.41 | $10,108 |
| 2026-09-11 | Faller Douglas Vincent | +4,211 | $1.47 | $6,190 |
| 2026-09-11 | Lindborg Stacy | +5,504 | $1.47 | $8,091 |
| 2026-09-11 | Tardugno Michael H | +5,824 | $1.47 | $8,561 |
| 2026-08-31 | Eylward Susan | -2,525 | $1.5643 | $3,950 |
| 2026-08-28 | Faller Douglas Vincent | +3,626 | $1.6 | $5,802 |
| 2026-08-28 | Eylward Susan | +2,525 | $1.6 | $4,040 |
| 2026-08-28 | Lindborg Stacy | +6,822 | $1.6 | $10,915 |
| 2026-08-28 | Tardugno Michael H | +7,371 | $1.6 | $11,794 |
| 2026-08-17 | Eylward Susan | -2,449 | $1.6303 | $3,993 |
| 2026-08-14 | Faller Douglas Vincent | +3,516 | $1.65 | $5,801 |
| 2026-08-14 | Eylward Susan | +2,449 | $1.65 | $4,041 |
| 2026-08-14 | Lindborg Stacy | +6,615 | $1.65 | $10,915 |
| 2026-08-14 | Tardugno Michael H | +7,147 | $1.65 | $11,793 |
| 2026-08-03 | Eylward Susan | -2,541 | $1.5651 | $3,977 |
| 2026-07-31 | Faller Douglas Vincent | +3,649 | $1.59 | $5,802 |
| 2026-07-31 | Eylward Susan | +2,541 | $1.59 | $4,040 |
| 2026-07-31 | Lindborg Stacy | +5,010 | $1.59 | $7,966 |
| 2026-07-31 | Braun Donald P | +6,180 | $1.59 | $9,826 |
| 2026-07-31 | Fritz Frederick J. | +6,934 | $1.59 | $11,025 |
| 2026-07-31 | Dentzer James E | +6,934 | $1.59 | $11,025 |
| 2026-07-31 | Tardugno Michael H | +6,358 | $1.59 | $10,109 |
| 2026-07-31 | Pellizzari Christine A | +6,934 | $1.59 | $11,025 |
| 2026-07-20 | Eylward Susan | -2,150 | $1.7816 | $3,830 |
| 2026-07-17 | Faller Douglas Vincent | +3,082 | $1.83 | $5,640 |
| 2026-07-17 | Eylward Susan | +2,150 | $1.83 | $3,935 |
| 2026-07-17 | Lindborg Stacy | +4,907 | $1.83 | $8,980 |
| 2026-07-17 | Tardugno Michael H | +4,603 | $1.83 | $8,423 |
| 2026-07-06 | Eylward Susan | -920 | $1.88 | $1,730 |
| 2026-07-02 | Faller Douglas Vincent | +1,308 | $1.91 | $2,498 |
| 2026-07-02 | Eylward Susan | +920 | $1.91 | $1,757 |
| 2026-07-02 | Lindborg Stacy | +2,534 | $1.91 | $4,840 |
| 2026-07-02 | Tardugno Michael H | +4,410 | $1.91 | $8,423 |
| 2026-06-18 | Lindborg Stacy | +1,803 | $1.82 | $3,281 |
| 2026-06-18 | Tardugno Michael H | +4,629 | $1.82 | $8,425 |
| 2026-06-05 | Lindborg Stacy | +1,593 | $2.06 | $3,282 |
| 2026-06-05 | Tardugno Michael H | +4,089 | $2.06 | $8,423 |
| 2026-05-22 | Lindborg Stacy | +1,491 | $2.2 | $3,280 |
| 2026-05-22 | Braun Donald P | +5,011 | $2.2 | $11,024 |
| 2026-05-22 | Fritz Frederick J. | +10,330 | $2.2 | $22,726 |
| 2026-05-22 | Dentzer James E | +11,148 | $2.2 | $24,526 |
| 2026-05-22 | Tardugno Michael H | +3,484 | $2.2 | $7,665 |
| 2026-05-22 | Pellizzari Christine A | +5,557 | $2.2 | $12,225 |
| 2026-01-02 | Faller Douglas Vincent | +12,667 | - | - |
| 2026-01-02 | Eylward Susan | +8,251 | - | - |
| 2026-01-02 | Bragg Kimberly | +9,050 | - | - |
| 2026-01-02 | Lindborg Stacy | +56,187 | - | - |
| 2026-01-02 | Braun Donald P | +5,881 | - | - |
| 2026-01-02 | Anwer Khursheed | +15,736 | - | - |
| 2026-01-02 | Fritz Frederick J. | +5,892 | - | - |
| 2026-01-02 | Dentzer James E | +4,405 | - | - |
| 2026-01-02 | Tardugno Michael H | +43,821 | - | - |
| 2026-01-02 | Pellizzari Christine A | +4,827 | - | - |